Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.
In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections. Escherichia coli was the most common isolate. Infections due to Enterobacter...
Gardado en:
| Publicado en: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society for Microbiology (ASM)
1985
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC176290/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3158277/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.27.3.422 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|